All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
Guidelines and recommendations for the use of ECP in the treatment of GvHD
Do you know... According to the SIdEM and GITMO recommendations, which statement best describes the optimal ECP treatment cycle for patients with cGvHD?
Question 1 / 1
Knowledge check | In a retrospective study by Lastovytska et al., what was the CR rate at Month 6 in patients with SR-aGvHD treated with ECP + ruxolitinib?
A
25%
B
40%
C
50%
D
65%
There is heterogeneity between treatment centers regarding extracorporeal photopheresis (ECP) scheduling, and the optimal treatment schedule for ECP in graft-versus-host disease (GvHD) is yet to be determined.
In the third chapter of this e-learning module, we provide an overview of the current guidelines and latest recommendations from expert groups, including the American Society for Apheresis (ASFA), alongside multiple European groups from Italy, Germany, and the UK, for the use of ECP for the treatment of acute and chronic GvHD.
Click through the slides below to learn more.
The next chapter of this e-learning module will be published shortly.
This educational resource is independently supported by Therakos. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which consideration most strongly guides your decision to escalate therapy in SR-aGvHD?
.webp&w=3840&q=75)